Adverse Events Associated With Treatment for Pan-Susceptible Tuberculosis in San Francisco

Janice K Louie; Chris Keh; Rocio Agraz-Lara; Allison Phillips; Susannah Graves

doi:10.1093/cid/ciac867

Adverse Events Associated With Treatment for Pan-Susceptible Tuberculosis in San Francisco

Clin Infect Dis. 2023 Mar 21;76(6):1121-1124. doi: 10.1093/cid/ciac867.

Authors

Janice K Louie^{1

2}, Chris Keh², Rocio Agraz-Lara¹, Allison Phillips¹, Susannah Graves¹

Affiliations

¹ Division of Population Health, San Francisco Department of Public Health, San Francisco, California, USA.
² Department of Medicine, University of California-San Francisco, San Francisco, California, USA.

PMID: 36322073
DOI: 10.1093/cid/ciac867

Abstract

Of 373 patients treated for drug-susceptible tuberculosis, 35.4% (46.2% aged ≥65 years) developed moderate/severe adverse events that required treatment interruption (34.8%), first-line drug discontinuation (26.2%, primarily pyrazinamide), second-line drug initiation (30.0%), and treatment duration up to 3.8 months longer. More safe and effective options are needed, including for the elderly.

Keywords: TB; adverse events; elderly; tuberculosis.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Aged
Antitubercular Agents / adverse effects
Disease Susceptibility
Humans
San Francisco
Treatment Outcome
Tuberculosis* / drug therapy
Tuberculosis, Multidrug-Resistant* / drug therapy

Substances

Antitubercular Agents